Search Results

The Xpert Xpress CoV-2/Flu/RSV plus test, performed on the GeneXpert Xpress System, is an automated multiplexed real-time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for use in the simultaneous in vitro qualitative detection and differentiation of severe acute respiratory syndrome coronavirus (SARS-CoV-2), influenza A, influenza B, and/or respiratory syncytial virus (RSV) viral RNA in nasopharyngeal swab and anterior nasal swab specimens collected from individuals with signs and symptoms of respiratory tract infection. Clinical signs and symptoms of respiratory tract infection due to SARS-CoV-2, influenza A, influenza B, and RSV can be similar.

The Xpert Xpress CoV-2/Flu/RSV plus test is intended for use in the differential detection of SARS-CoV-2, influenza A, influenza B and/or RSV RNA and aids in the diagnosis of COVID-19, influenza and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings. SARS-CoV-2, influenza A, influenza B, and RSV viral RNA are generally detectable in nasopharyngeal swab and anterior nasal swab specimens during the acute phase of infection.

Positive results are indicative of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. The agent (s) detected by the Xpert Xpress CoV-2/Flu/RSV plus test may not be the definite cause of the disease.

Negative results do not preclude SARS-CoV-2, influenza A, influenza B and/or RSV infection. The results of this test should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

The Xpert Xpress CoV-2/Flu/RSV plus test is an automated in vitro diagnostic test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Flu A, Flu B, and RSV viral RNA in nasopharyngeal swab (NPS) and anterior nasal swab (NS) specimens collected from individuals showing signs and symptoms of respiratory viral infection.

The Xpert Xpress CoV-2/Flu/RSV plus test is performed on GeneXpert Xpress System, which consist of a GeneXpert IV instrument that executes sample preparation, nucleic acid amplification and real-time fluorescent signal detection for the tests, and a GeneXpert Hub with preloaded GeneXpert Xpress software for running the tests and viewing the test results. The GeneXpert Hub accessory integrates the computer, touchscreen monitor and barcode scanner. Each of the GeneXpert modules in the GeneXpert IV instrument can perform independent sample preparation and testing. The GeneXpert Xpress System requires the use of single-use disposable cartridges that hold the RT-PCR reagents and host sample purification, nucleic acid amplification, and detection of the target sequences. Because the cartridges are self-contained, cross-contamination between samples is minimized.

The Xpert Xpress CoV-2/Flu/RSV plus test includes reagents for the detection of SARS-CoV-2, Flu A, Flu B and RSV viral RNA from NPS and NS specimens. The primers and probes in the Xpert Xpress CoV-2/Flu/RSV plus test are designed to amplify and detect unique sequences in the genes that encode the following proteins: SARS-CoV-2 nucleocapsid (N), SARS-CoV-2 envelope (E), SARS-CoV-2 RNA-dependent RNA polymerase (RdRP), influenza A matrix (M), influenza A basic polymerase (PB2), influenza A acidic protein (PA), influenza B matrix (M), influenza B non-structural protein (NS), and the RSV A and RSV B nucleocapsid.

A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert instrument. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The Xpert Xpress CoV-2/Flu/RSV plus test is designed for use with NPS or NS specimens collected with nylon flocked swabs and placed into viral transport medium (VTM), Universal Transport Medium (UTM), or eNAT®. The ancillary specimen collection kits, swabs and transport media validated for use with the Xpert Xpress CoV-2/Flu/RSV plus test included:

• Nasopharyngeal Sample Collection Kit for Viruses

• Copan UTM® 3C057N (Flexible Minitip Flocked Swab with UTM® Medium without Beads)
• Copan eNAT® Molecular Collection and Preservation Medium P/N 6U074S01 (Flexible Minitap Flocked Swab with eNAT® Medium)

• Nasal Sample Collection Kit for Viruses

• Copan UTM® 3C064N (Regular Flocked Swab with UTM® Medium without Beads)
• Copan eNAT® Molecular Collection and Preservation Medium P/N 6U073S01 (Regular Flocked Swab with eNAT® Medium)

• Alternatively, swabs and transport media can be obtained separately:

• Nylon flocked swab (Copan P/N 502CS01, 503CS01)
• Viral Transport Medium, 3 mL (Copan P/N 330C, 3C047N, BD Universal Transport Medium, Remel M4RT, or Remel M5)

The ancillary reagents allow NPS and NS specimens from patients to be collected, preserved and transported to laboratory prior to analysis with the Xpert Xpress CoV 2/Flu/RSV plus test.

Based on the provided FDA 510(k) clearance letter and summary, here's an analysis of the acceptance criteria and study that proves the device meets them:

Important Note: This document describes a "Special 510(k) submission." This type of submission is used when changes are made to a previously cleared device that do not affect its fundamental technology, intended use, or safety/effectiveness. In this specific case, the changes were to the Assay Definition File (ADF) – essentially software parameter settings. Therefore, the "study that proves the device meets the acceptance criteria" largely relies on re-analysis of existing studies from the original device clearance (K242071) rather than entirely new, large-scale clinical trials.

1. Table of Acceptance Criteria and Reported Device Performance

The provided document doesn't explicitly state quantitative acceptance criteria in a dedicated table. However, since this is a Special 510(k) for software parameter changes, the primary "acceptance criteria" appear to be demonstrating non-inferiority or equivalency to the previously cleared predicate device in terms of:

• Valid Test Runs: The number of tests that yield a valid result.
• Non-Determinate (ND) Test Results: The number of tests that do not yield a definitive positive or negative result (e.g., "NO RESULT").
• Performance Claims: That the modifications did not negatively impact the overall analytical and clinical performance claims established for the predicate device (sensitivity, specificity for detecting SARS-CoV-2, Flu A, Flu B, and RSV).

Inferred Acceptance Criteria and Reported Performance:

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size:
  • Main analysis: 16,264 test results. This number represents the re-analysis of "verification, validation and flex studies data from the original studies."
  • SARS-CoV-2 only test mode analysis: 25 test results.
  • Simulated conditions for revised algorithm: The document mentions "Test cartridges were simulated to generate SARS-CoV-2 INVALID and SPC FAIL conditions," but does not explicitly state the number of simulated tests.
• Data Provenance: The data used for re-analysis originated from the "original studies" (K242071 submission). The document does not specify the country of origin or whether these original studies were retrospective or prospective, though typical clinical validation studies for IVDs are often prospective. Given it references "flex study," those can sometimes include both retrospective and prospective elements.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The document does not provide information on the number or qualifications of experts used to establish the ground truth. This is likely because the ground truth was established during the original predicate device clearance (K242071) and this Special 510(k) focused on demonstrating equivalence in specific software-related metrics through re-analysis. For IVD devices like this, ground truth is typically established by comparing against a highly sensitive and specific reference method (e.g., an FDA-cleared laboratory developed test or a combination of clinical diagnosis and other accepted testing methods).

4. Adjudication Method for the Test Set

The document does not specify any adjudication method (e.g., 2+1, 3+1, none) for the test set. Again, this specific submission involved re-analysis of existing data rather than new clinical trials where such adjudication might be more explicitly detailed if human reads were involved. For an automated RT-PCR test, adjudication as typically understood for image-based AI would not be directly applicable.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted or is not mentioned in this document. This is an in vitro diagnostic device (RT-PCR test), not an AI-assisted diagnostic imaging system that would typically involve human readers interpreting images with or without AI assistance. The device is fully automated.

6. Standalone Performance (Algorithm Only)

Yes, the performance evaluated here is inherently standalone (algorithm only). The Xpert Xpress CoV-2/Flu/RSV plus is an automated RT-PCR test system. Its output is directly generated by the instrument and its embedded software (ADF). The "performance data" detailed in section 18.5 describes how the device's algorithmic and software changes affected its ability to produce valid results and interpret them correctly, without human intervention in the result generation.

7. Type of Ground Truth Used

The document does not explicitly state the type of ground truth used for the original studies, beyond stating "analytical, clinical and flex studies data." For RT-PCR assays, the ground truth for clinical performance is typically established by:

• Clinical Reference Method: Comparison against a highly sensitive and specific laboratory reference method (e.g., another FDA-cleared or EUA-authorized RT-PCR test, or a composite reference standard using multiple methods).
• Clinical Diagnosis/Outcomes Data (less common for purely diagnostic tests): While the device aids in diagnosis ("aids in the diagnosis of COVID-19, influenza and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings"), the performance claims themselves are based on detection of viral RNA, rather than patient outcomes as primary ground truth.

Given the nature of a molecular diagnostic test for viral RNA, the ground truth for the performance claims (sensitivity, specificity) of the original device would have been established by comparing the device's results against a highly reliable reference molecular test, often considered the "gold standard" for pathogen detection.

8. Sample Size for the Training Set

The document does not provide information on the sample size for the training set. This is because:

• This is an RT-PCR test, not a deep learning AI model that undergoes "training" in the typical machine learning sense. The "algorithm" here refers to the pre-defined logical rules and parameters within the Assay Definition File (ADF) for interpreting RT-PCR signals.
• The re-analysis was performed on verification, validation, and flex studies data, which are typically considered test or validation sets in the context of device development, not training sets.

9. How the Ground Truth for the Training Set Was Established

As noted above, a "training set" and associated ground truth establishment in the context of deep learning AI are not applicable to this RT-PCR device. The "ground truth" for the device's performance relies on the known characteristics of the viral targets and the performance of the RT-PCR chemistry against reference methods.

Ask a specific question about this device

The Xpert Xpress CoV-2/Flu/RSV plus test, performed on the GeneXpert Dx and GeneXpert Infinity Systems, is an automated multiplexed real-time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for use in the simultaneous in vitro qualitative detection and differentiation of severe acute respiratory syndrome coronavirus (SARS-CoV-2), influenza A, influenza B, and/or respiratory syncytial virus (RSV) viral RNA in nasopharyngeal swab and anterior nasal swab specimens collected from individuals with signs and symptoms of respiratory tract infection. Clinical signs and symptoms of respiratory tract infection due to SARS-CoV-2, influenza A, influenza B, and RSV can be similar.

The Xpert Xpress CoV-2/Flu/RSV plus test is intended for use in the differential detection of SARS-CoV-2, influenza A, influenza B and/or RSV RNA and aids in the diagnosis of COVID-19, influenza and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings. SARS-CoV-2, influenza A, influenza B, and RSV viral RNA are generally detectable in nasopharyngeal swab and anterior nasal swab specimens during the acute phase of infection.

Positive results are indicative of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. The agent (s) detected by the Xpert Xpress CoV-2/Flu/RSV plus test may not be the definite cause of the disease.

Negative results do not preclude SARS-CoV-2, influenza A, influenza B and/or RSV infection. The results of this test should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

The Xpert Xpress CoV-2/Flu/RSV plus test is an automated in vitro diagnostic test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Flu A, Flu B, and RSV viral RNA in nasopharyngeal swab (NPS) and anterior nasal swab (NS) specimens collected from individuals showing signs and symptoms of respiratory viral infection.

The Xpert Xpress CoV-2/Flu/RSV plus test is performed on GeneXpert Instrument Systems (GeneXpert Dx, GeneXpert Infinity-48s and GeneXpert Infinity-80 systems, GeneXpert System with Touchscreen), which consist of an instrument, computer or touchscreen, and preloaded software for running tests and viewing the results. The GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequences in simple or complex samples using real-time reverse transcription (RT)-polymerase chain reaction (PCR) and PCR technology. Depending on the instrument, the GeneXpert Instrument Systems can have from 1 and up to 80 randomly accessible modules, each capable of performing separate sample preparation and real-time RT-PCR and PCR tests. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE® thermocycler for performing real-time RT-PCR and PCR as well as detection. The systems require the use of single-use disposable cartridges that hold the RT-PCR reagents and host sample purification, nucleic acid amplification, and detection of the target sequences. Because the cartridges are self-contained, cross-contamination between samples is minimized.

The Xpert Xpress CoV-2/Flu/RSV plus test includes reagents for the detection of SARS-CoV-2, Flu A, Flu B and RSV viral RNA from NPS and NS specimens. The primers and probes in the Xpert Xpress CoV-2/Flu/RSV plus test are designed to amplify and detect unique sequences in the genes that encode the following proteins: SARS-CoV-2 nucleocapsid (N), SARS-CoV-2 envelope (E), SARS-CoV-2 RNA-dependent RNA polymerase (RdRP), influenza A matrix (M), influenza A basic polymerase (PB2), influenza A acidic protein (PA), influenza B matrix (M), influenza B non-structural protein (NS), and the RSV A and RSV B nucleocapsid.

A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert instrument. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The Xpert Xpress CoV-2/Flu/RSV plus test is designed for use with NPS or NS specimens collected with nylon flocked swabs and placed into viral transport medium (VTM), Universal Transport Medium (UTM), or eNAT®.

The FDA 510(k) Clearance Letter for the Xpert Xpress CoV-2/Flu/RSV plus device describes modifications to an existing PCR test. The information provided outlines the acceptance criteria implicitly through the modifications and performance data presented. However, it's important to note that this document is a 510(k) summary, which provides a high-level overview of the submission and does not contain the full details of all studies conducted. Therefore, some requested information may not be explicitly present in the provided text.

Based on the provided text, here's an analysis:

Summary of Acceptance Criteria and Device Performance

The core of this 510(k) submission is a "Special 510(k)" which means the device (Xpert Xpress CoV-2/Flu/RSV plus) is largely the same as a previously cleared predicate device (K231481), but with minor design changes. Therefore, the acceptance criteria are implicitly tied to demonstrating that these changes do not negatively impact the previously established performance claims of the predicate device.

Specifically, the modifications include:

1. Turning off Signal Loss Detection (SLD) for the Flu B channel.
2. Revising the result reporting algorithm for the SARS-CoV-2 only test mode.
   • Previously: SARS-CoV-2 NEGATIVE if SARS-CoV-2 analyte result is INVALID and SPC is FAIL.
   • Revised: INVALID GeneXpert test result if SARS-CoV-2 analyte result is INVALID and SPC is FAIL.

Table of Acceptance Criteria (Implicit) and Reported Device Performance:

Study Details Proving Acceptance:

1. Sample sizes used for the test set and the data provenance:

   • Test Set (Re-analysis Data):
     • Analytical Test Results: 15,645
     • Clinical, Reproducibility-Precision, and Single-Site Precision Test Results: 9,525 (comprising 8,535 specimens and 990 controls).
   • Data Provenance: The document does not explicitly state the country of origin or whether the data was retrospective or prospective for the re-analyzed verification and validation studies. However, since it refers to "original studies" (K231481), it implies data previously collected and used for the predicate device's clearance.

2. Number of experts used to establish the ground truth for the test set and their qualifications:

   • This information is not provided in the given text. For an in vitro diagnostic (IVD) device like this, ground truth is typically established by comparative methods (e.g., another FDA-cleared PCR test, or a consensus of multiple clinical/laboratory results), not by human expert readers in the way an imaging AI device might use radiologists. The "ground truth" for this device's performance would be the presence or absence of viral RNA, determined by well-established laboratory methods.

3. Adjudication method for the test set:

   • This information is not provided and is generally not applicable to the type of re-analysis done for an IVD device where ground truth is established by laboratory methods rather than human interpretation requiring adjudication.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done:

   • No, an MRMC study was not done. This type of study is primarily relevant for imaging AI devices that assist human readers in interpretation. This device is an automated, standalone diagnostic test.

5. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

   • Yes, implicitly. The re-analysis of performance data, particularly the comparison between the original and updated Assay Definition Files (ADF) and the verification of the revised algorithm, represents the standalone performance of the device's software (algorithm) logic. The device itself is an automated system.

6. The type of ground truth used:

   • Implicitly, the ground truth was established by laboratory reference methods (e.g., RT-PCR) for the original clinical specimens. For the re-analysis, the "ground truth" for evaluating the impact of the changes was the consistency of results and proper operation of the updated algorithm against the expected behavior, confirmed by the original analytical and clinical study data. For the SARS-CoV-2 algorithm change, "test cartridges were simulated to generate SARS-CoV-2 INVALID and SPC FAIL conditions," meaning the ground truth for this specific verification was a controlled simulation designed to trigger the specific algorithm conditions.

7. The sample size for the training set:

   • Not explicitly stated in relation to this Special 510(k) submission. As this is a modification to an existing device, it's likely that the original training/development data for the predicate device were used, but the size of that dataset is not provided here. The 15,645 analytical test results and 9,525 clinical/precision test results mentioned are re-analyzed verification and validation data, not training data.

8. How the ground truth for the training set was established:

   • Not explicitly stated in the provided text. For an RT-PCR diagnostic, the ground truth for training/development would typically involve characterized clinical samples or contrived samples with known viral concentrations and presence/absence of targets, verified by highly sensitive and specific reference methods (e.g., sequencing, confirmatory PCRs, or sometimes clinical outcomes correlated with virology).

Ask a specific question about this device

The Xpert® C. difficile/Epi test is a qualitative in vitro diagnostic test for detection of toxin B gene sequences and for presumptive identification of 027/NAP1/BI strains of toxigenic Clostridioides difficile from unformed (liquid or soft) stool specimens collected from patients suspected of having C. difficile infection (CDI). Presumptive identification of 027/NAP1/BI strains of C. difficile is by detection of binary toxin (CDT) gene sequences and the single base pair deletion at nucleotide 117 in the tcdC gene. The tcdC gene encodes for a negative regulator in C. difficile toxin production. The test is performed on the GeneXpert® Instrument Systems and utilizes automated real-time polymerase chain reaction (PCR) to detect toxin gene sequences associated with toxin producing C. difficile. The Xpert® C. difficile/Epi test is intended as an aid in the diagnosis of CDI. Detection of 027/NAP/Bl strains of C. difficile by the Xpert® C. difficile/Evi test is presumptive and is solely for enidemiological purposes and is not intended to guide or monitor treatment for C. difficile infections. Concomitant culture is necessary only if further typing or organism recovery is required.

The Xpert C. difficile/Epi test is an automated in vitro diagnostic test for qualitative detection of toxin producing Clostridioides difficile (formerly known as Clostridium difficile) directly from unformed (liquid or soft) stool specimens of patients suspected of having Clostridioides difficile infection (CDI). The test detects the toxin B gene (tcdB), the binary toxin (CDT) gene, and the single base pair deletion at nucleotide 117 (tcdCΔ117) within the gene encoding TcdC, a negative regulator of toxin production. The combined presence of the genes encoding toxin B and binary toxin and the tcdCA117 deletion has been associated with a hypervirulent C. difficile strain known as 027/NAP1/BI, which has been associated with severe disease outbreaks in healthcare facilities worldwide.

The test is performed on the GeneXpert® Instrument Systems (comprised of the GeneXpert® Dx System. GeneXpert® System with Touchscreen, and GeneXpert® Infinity System). In the GeneXpert® Instrument Systems, sample preparation, amplification, and real-time detection are all fully automated and completely integrated. The single-use disposable Xpert C. difficile/Evi cartridge, required by the platform for use, holds the PCR reagents and hosts the PCR process. Because the cartridge is self-contained, cross-contamination between samples is minimized.

The Xpert C. difficile/Epi test includes reagents for the detection of toxigenic C. difficile and the detection of sequences for presumptive identification of 027/NAP 1/BI strains. In addition, the test reagents include an internal sample processing control (SPC) to ensure adequate processing of the target bacteria and to monitor the presence of inhibitor(s) in the PCR Assay. The SPC also ensures that the PCR conditions (temperature and time) are appropriate for the amplification reaction and that the PCR reagents are functional. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

The Xpert C. difficile/Evi test system performs sample preparation and real-time, multiplex polymerase chain reaction (PCR) for detection of target-specific DNA. A swab is inserted into the stool specimen and then placed in a tube containing Sample Reagent. Following brief vortexing, the content of the Sample Reagent is transferred to the Sample Chamber of the disposable fluidic cartridge (the Xpert C. difficile/Epi cartridge). The user initiates a test from the system user interface of the GeneXpert® Instrument Systems and places the cartridge with sample into a GeneXpert® instrument system which performs hands-off real-time PCR for detection of C. difficile DNA.

Depending on the specific instrument, a GeneXpert® instrument system may contain 1-80 modules, each of which are randomly accessible and capable of performing separate sample preparation and real-time PCR tests for the detection of gene sequences for C. difficile toxin B and binary toxin and the tcdCA117 deletion in less than 45 minutes. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE® thermocycler for performing real-time PCR and detection.

Each instrument in the GeneXpert® instrument family is equipped with a Windows OS-based personal computer that is preloaded with software applications for running the tests and viewing the results, as described in Table 1.

The provided document is a 510(k) summary for the Cepheid Xpert C. difficile/Epi test. It details the device's characteristics, intended use, and performance studies conducted to demonstrate substantial equivalence to a predicate device and compliance with special controls.

Here's a breakdown of the requested information based on the provided text:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state formal acceptance criteria with numerical targets (e.g., minimum sensitivity/specificity percentages). Instead, it summarizes "verification studies" to demonstrate performance and compliance. The key performance indicators mentioned relate to agreement with expected results and accurate identification of strains.

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Sample Size for Test Set:
  • Prepared Cartridge Hold Time Study: Not explicitly stated how many "contrived positive" and "negative" samples were used, only that they were held for "various times under three (3) hold environments."
  • Functional Testing: Not explicitly stated how many "contrived positive" and "negative" samples were used.
  • Inclusivity Study: 26 C. difficile strains were tested (18 from previous study K110203 and 8 additional strains for K243730).
• Data Provenance: The document does not specify the country of origin of the data or whether the studies were retrospective or prospective. The studies mentioned (Hold Time, Functional Testing, Inclusivity) appear to be laboratory-based verification studies, rather than clinical trials with patient samples.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

The document does not mention the use of experts to establish ground truth for the test set. The performance studies appear to be analytical verification studies using contrived samples and known bacterial strains, implying that the ground truth for these studies was established by laboratory methods rather than expert consensus on clinical samples.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

The document does not describe any adjudication method for establishing ground truth, as the studies are analytical verification studies using controlled samples with known statuses (contrived positive/negative, specific C. difficile strains).

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

A multi-reader multi-case (MRMC) comparative effectiveness study was not done. The device is a diagnostic assay (Nucleic Acid Amplification Test) for infectious disease, not an AI-powered image analysis tool requiring human reader interpretation. No mention of AI assistance or human readers is present.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, the studies described (Prepared Cartridge Hold Time, Functional Testing, Inclusivity) assess the performance of the Xpert C. difficile/Epi test in a standalone manner. The device is an automated in vitro diagnostic test that performs sample preparation, amplification, and real-time detection without human intervention in the result determination process. It's an "algorithm-only" performance in the sense that the instrument provides a final result based on its internal processes.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The ground truth for the verification studies was based on:

• Known status of contrived samples: "contrived positive (C. difficile cells added to negative matrix) and negative (negative matrix only) samples" for hold time and functional testing.
• Known bacterial strains: "C. difficile strains selected to broadly represent the majority of C. difficile toxinotypes encountered in practice" for the inclusivity study, where accurate identification of these known strains served as the ground truth.

8. The sample size for the training set

The document does not mention a "training set" in the context of machine learning or AI. This is a diagnostic assay, and its development likely involved traditional analytical validation and verification rather than an AI model requiring a training set.

9. How the ground truth for the training set was established

Not applicable, as no training set (in the AI/ML sense) is mentioned or implied for this device.

Ask a specific question about this device

The Xpert® FII & FV test is a qualitative in vitro diagnostic genotyping test for the detection of Factor V alleles from sodium citrate or EDTA anticoagulated whole blood. The test is performed on the GeneXpert® Instrument Systems. This test is intended to provide results for Factor II (G20210A) and Factor V Leiden (G1691A) mutations as an aid in the diagnosis in individuals with suspected thrombophilia.

Xpert FII & FV is an automated genotyping test for detecting Factor II and Factor V normal and mutant alleles directly from sodium citrate or EDTA anticoagulated whole blood specimens. Blood specimens are drawn into either sodium citrate or EDTA anticoagulant tubes. Following brief mixing of the sample. 50 uL of the blood sample is transferred to the bottom wall of the Sample opening of the Xpert FII & FV test cartridge. The user initiates a test from the system user interface and places the cartridge into the GeneXpert Instrument System.

The Xpert FII & FV test includes reagents for the detection of Factor II and Factor V normal and mutant alleles. The primers and probes in the Xpert FII & FV test determine the genotype of the Factor II gene (at position 20210) and/or the Factor V gene (at position 1691). The test includes a Sample Processing Control (SPC) to confirm adequate processing and to monitor the presence of inhibitor(s) in the PCR assay. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

The GeneXpert Instrument Systems family is comprised of GeneXpert Dx System, GeneXpert Infinity System, and GeneXpert System with Touchscreen. The GeneXpert Instrument Systems automate and integrate sample processing, nucleic acid amplification and detection of the target sequences in simple or complex samples using real-time polymerase chain reaction (PCR). The systems consist of an instrument, computer or touchscreen, and preloaded software for running the tests and viewing the results. The GeneXpert Instrument Systems require the use of singleuse disposable cartridges that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized.

The GeneXpert Instrument Systems have 1 to 80 modules (depending upon the instrument) that are each capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE® thermocycler for performing real-time PCR and detection.

The Xpert FII & FV test performed on the GeneXpert Instrument Systems provides results in approximately 30 minutes.

This document is a 510(k) summary for the Xpert FII & FV diagnostic test, seeking to remove a limitation statement and make minor branding/catalog number changes. It does not contain a study explicitly detailing acceptance criteria and performance against those criteria for the current submission. Instead, it refers to prior clearance (K082118) for the clinical validation supporting the removal of the limitation statement, and asserts that the current changes do not impact performance.

Therefore, the following information is extracted or inferred based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance:

The document explicitly states: "No new performance data were provided in this submission." The basis for substantial equivalence relies on the device being identical to its predicate (K223046) in all technological characteristics relevant to performance. The one significant change (removal of the pediatric patient limitation) is supported by prior clinical validation data (K082118). Since no new performance data or acceptance criteria are presented for this specific submission, this table cannot be fully completed from the provided text.

However, based on the nature of a genetic mutation detection system, typical acceptance criteria would involve analytical sensitivity, analytical specificity, and clinical performance (e.g., concordance with a gold standard). Without the original K082118 submission, specific numerical criteria are not available.

2. Sample Size Used for the Test Set and Data Provenance:

• Sample Size: Not explicitly stated in this document. The document refers to "clinical validation data that was submitted and reviewed as part of the original device clearance (K082118)" as the basis for removing the pediatric limitation. The sample size for that original study is not provided here.
• Data Provenance: Not explicitly stated in this document. Given it's a 510(k) for a US market device, it is likely the original clinical validation (K082118) included US data, but this is not confirmed. It refers to "clinical validation data," which typically implies prospective collection of patient samples.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications:

• Not explicitly stated in this document. This level of detail would typically be found in the original clinical validation report (K082118). For genotyping, ground truth is usually established by orthogonal molecular methods, not primarily by expert consensus in the same way as imaging or pathology interpretation.

4. Adjudication Method for the Test Set:

• Not applicable/Not mentioned. For genetic tests where the ground truth is often established through well-defined molecular techniques (e.g., Sanger sequencing or a validated reference method), adjudication by multiple experts in the traditional sense (like for imaging reads) is generally not performed. The ground truth is objective.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:

• No, an MRMC comparative effectiveness study was not done. This type of study is relevant for interpretive tasks (e.g., radiologists reading images) where human performance is being evaluated and compared with and without AI assistance. The Xpert FII & FV is an automated genotyping test; it does not involve human readers interpreting results in the same manner.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:

• Yes, the performance characteristics mentioned (e.g., analytical sensitivity, specificity) for a molecular diagnostic test like the Xpert FII & FV are inherently "standalone" in nature. The device itself performs the assay and provides a qualitative genotype call. The results are automated and interpreted by the diagnostic software.

7. The Type of Ground Truth Used:

• Not explicitly stated in this document, but for genetic tests, the ground truth is typically established by orthogonal molecular methods, such as Sanger sequencing or another highly accurate, validated reference genotyping method. It is not based on expert consensus, pathology, or outcomes data in the way these terms are typically used for imaging or disease diagnosis.

8. The Sample Size for the Training Set:

• Not explicitly stated in this document. The device uses real-time PCR for detection, and while there might be algorithm tuning within the software, the foundational "training" often refers to the design and optimization of primers and probes, and establishment of cut-offs, rather than machine learning on a large training set of clinical samples. The document refers to "clinical validation data" for performance, but not specifically to a training set size for an algorithm.

9. How the Ground Truth for the Training Set was Established:

• Not explicitly stated in this document. This would be part of the original developmental studies for the device (predating K082118). For a PCR-based test, ground truth for developing and optimizing the assay would involve samples with known genotypes confirmed through reference methods.

Ask a specific question about this device

The Xpert Xpress CoV-2 plus test, performed on the GeneXpert Xpress System, is a rapid real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal and anterior nasal swab specimens collected from individuals with signs and symptoms of respiratory tract infection.

The Xpert Xpress CoV-2 plus test is intended for use as an aid in the diagnosis of COVID-19 if used in conjunction with other clinical, epidemiologic, and laboratory findings. Positive results are indicative of the presence of SARS-CoV-2 RNA. Positive results do not rule out bacterial infection or co-infection with other pathogens.

Negative results do not preclude SARS-CoV-2 infection. The results of this test should not be used as for diagnosis and patient management decisions.

The Xpert Xpress CoV-2 plus test is a rapid, automated in vitro diagnostic test for the qualitative detection of viral RNA from SARS-CoV-2 in nasopharyngeal swab (NPS) and anterior nasal swab (NS) specimens collected from individuals with signs and symptoms of respiratory tract infection.

The Xpert Xpress CoV-2 plus test is performed on GeneXpert Xpress System, which consist of a GeneXpert IV instrument that executes sample preparation, nucleic acid amplification and real-time fluorescent signal detection for the tests, and a GeneXpert Hub with preloaded GeneXpert Xpress software for running the tests and viewing the test results. The GeneXpert Hub accessory integrates the computer, touchscreen monitor and barcode scanner. Each of the GeneXpert modules in the GeneXpert IV instrument can perform independent sample preparation and testing. The GeneXpert Xpress System requires the use of single-use disposable cartridges that hold the RT-PCR reagents and host sample purification, nucleic acid amplification, and detection of the target sequences. Because the cartridges are selfcontained, cross-contamination between samples is minimized.

The Xpert Xpress CoV-2 plus test includes reagents for the detection of viral RNA from SARS-CoV-2 in NPS and NS specimens. The primers and probes in the Xpert Xpress CoV-2 plus test are designed to amplify and detect unique sequences in the genes that encode the following SARS-CoV-2 proteins: nucleocapsid (N2), envelope (E), and RNA-dependent RNA polymerase (RdRP). A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge serving as internal controls. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The Xpert Xpress CoV-2 plus test is designed for use with NPS or NS specimen collected with nylon flocked swabs and placed into viral transport medium (VTM), Universal Transport Medium (UTM) or eNAT®.

Acceptance Criteria and Study for Xpert Xpress CoV-2 plus

The Xpert Xpress CoV-2 plus test is a rapid real-time RT-PCR test for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal and anterior nasal swab specimens. The study aims to demonstrate substantial equivalence to a predicate device (K230440) by evaluating its analytical and clinical performance.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Sizes and Data Provenance

• Test Set (Clinical Performance):

  • Total specimens: 1783
    • NPS (Nasopharyngeal Swab): 883
    • NS (Anterior Nasal Swab): 900
  • Data Provenance: Prospective clinical specimens collected from individuals showing signs and symptoms of respiratory infection in the United States (22 geographically diverse CLIA-waived sites). Data was collected in 2022.

• Analytical Performance Test Sets:

  • Limit of Detection (LoD):
    • NPS-UTM/VTM: At least 40 replicates (2 reagent lots x 20 replicates)
    • NPS-eNAT: At least 40 replicates (2 reagent lots x 20 replicates)
    • NS-UTM/VTM: At least 40 replicates (2 reagent lots x 20 replicates)
    • WHO First International Standard (NS-UTM/VTM): 20 replicates
  • Analytical Reactivity (Wet-testing): 61 SARS-CoV-2 strains, 3 replicates per strain (total 183 tests).
  • Analytical Specificity (Wet-testing): 62 microorganisms, 3 replicates per organism (total 186 tests).
  • Microbial Interference: 18 commensal microorganisms, 8 replicates per strain (total 144 tests) with SARS-CoV-2.
  • Potentially Interfering Substances: 23 substances, 8 replicates for negative samples and 8 replicates for positive samples (total up to 368 tests, plus re-tests).
  • Carryover Contamination: 40 positive samples, 42 negative samples.
  • Reproducibility: 3 panel members (Negative, Low Pos, Mod Pos), 90 observations per panel member (3 Sites x 3 Operators x 1 Lot x 5 Days x 1 Run x 2 Replicates = 90). Total 270 observations.

3. Number of Experts and Qualifications for Ground Truth (Test Set)

The document does not explicitly state the number of experts used to establish the ground truth for the clinical test set or their specific qualifications (e.g., radiologist with 10 years of experience). However, the ground truth was established by a "U.S. FDA-cleared molecular respiratory panel that included SARS-CoV-2," indicating an established and validated laboratory method. Discrepant results were investigated using a "U.S FDA EUA SARS-CoV-2 molecular test," further relying on FDA-authorized assays as the reference standard.

4. Adjudication Method (Test Set)

The adjudication method used for the clinical test set was a discrepant analysis. "Discrepant results between Xpert Xpress CoV-2 plus and the comparator were investigated using a U.S FDA EUA SARS-CoV-2 molecular test." This implies that for any cases where the Xpert Xpress CoV-2 plus result differed from the initial FDA-cleared comparator panel, a third, independent FDA EUA molecular test was used to determine the true positive or negative status.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

There is no MRMC comparative effectiveness study mentioned in the provided text. The study focuses on the standalone performance of the device against a comparator device, not on human reader performance with or without AI assistance.

6. Standalone Performance Study

Yes, a standalone performance study was done. The entire "Performance Studies" section (1.4) details the analytical and clinical performance of the device itself (algorithm only, without human-in-the-loop performance). The clinical performance evaluation directly compares the Xpert Xpress CoV-2 plus test results to those of an FDA-cleared molecular respiratory panel.

7. Type of Ground Truth Used

For the clinical performance study, the ground truth was established by an FDA-cleared molecular respiratory panel and, in cases of discrepancy, by a U.S. FDA EUA SARS-CoV-2 molecular test. This falls under the category of reference standard laboratory testing rather than expert consensus, pathology, or outcomes data.

For analytical performance studies, the ground truth was established by spiking known concentrations/quantities of inactivated SARS-CoV-2 virus, genomic RNA, or other microorganisms into negative matrices, or by using established international standards (e.g., WHO First International Standard).

8. Sample Size for the Training Set

The document does not mention the sample size for the training set. This is a premarket notification (510(k)) and focuses on the performance testing of the final device, not on the developmental or training phases of its underlying algorithm. As a PCR-based diagnostic, it's unlikely to have a "training set" in the same sense as an AI/ML-based device; its analytical performance is determined by the specific primers and probes and their chemical/biological interactions.

9. How the Ground Truth for the Training Set was Established

Since no "training set" is explicit for this PCR diagnostic, there is no information provided on how its ground truth might have been established. The development of PCR assays typically involves careful design and validation of primers and probes against known genomic sequences and wet-lab testing with characterized samples, rather than machine learning training on a dedicated dataset.

Ask a specific question about this device

The Xpert Xpress CoV-2/Flu/RSV plus test, performed on the GeneXpert Xpress System, is an automated multiplexed real-time reverse transcriptase polymerase chain reaction (RT-PCR) test intended for use in the simultaneous in vitro qualitative detection and differentiation of severe acute respiratory syndrome coronavirus (SARS-CoV-2), influenza A, influenza B, and/or respiratory syncytial virus (RSV) viral RNA in nasopharyngeal swab anterior nasal swab specimens collected from individuals with signs and symptoms of respiratory tract infection. Clinical signs and symptoms of respiratory tract infection due to SARS-CoV-2, influenza B, and RSV can be similar.

The Xpert Xpress CoV-2/Flu/RSV plus is intended for use in the differential detection of SARS-CoV-2, influera A, influenza B, and/or RSV RNA and aids in the diagnosis of COVID-19, influenza, and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings. SARS-CoV-2, influenza A. influenza B, and RSV viral RNA are generally detectable in nasopharyngeal swab and anterior nasal swab specimens during the acute phase of infection.

Positive results are indicative of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. The agent (s) detected by the Xpert Xpress CoV-2/Flu/RSV plus test may not be the definite cause of the disease.

Negative results do not preclude SARS-CoV-2, influenza A virus, and/or RSV infection. The results of this test should not be used as the sole basis for treatment or other patient management decisions.

The Xpert Xpress CoV-2/Flu/RSV plus test is an automated in vitro diagnostic test for the simultaneous qualitative detection and differentiation of SARS-CoV-2. Flu A. Flu B. and RSV viral RNA in nasopharyngeal swab (NPS) and anterior nasal swab (NS) specimens collected from individuals showing signs and symptoms of respiratory viral infection.

The Xpert Xpress CoV-2/Flu/RSV plus test is performed on GeneXpert Xpress System, which consist of a GeneXpert IV instrument that executes sample preparation, nucleic acid amplification and real-time fluorescent signal detection for the tests, and a GeneXpert Hub with preloaded GeneXpert Xpress software for running the tests and viewing the test results. The GeneXpert Hub accessory integrates the computer, touchscreen monitor and barcode scanner. Each of the GeneXpert modules in the GeneXpert IV instrument can perform independent sample preparation and testing. The GeneXpert Xpress System requires the use of single-use disposable cartridges that hold the RT-PCR reagents and host sample purification, nucleic acid amplification, and detection of the target sequences. Because the cartridges are self-contained, cross-contamination between samples is minimized.

The Xpert Xpress CoV-2/Flu/RSV plus test cartridge includes reagents for the detection of SARS-CoV-2, Flu A, Flu B and RSV viral RNA from NPS and NS specimens. The primers and probes in the Xpert Xpress CoV-2/Flu/RSV plus test are designed to amplify and detect unique sequences in the genes that encode the following proteins: SARS-CoV-2 nucleocapsid (N), SARS-CoV-2 envelope (E), SARS-CoV-2 RNA-dependent RNA polymerase (RdRP), influenza A matrix (M), influenza A basic polymerase (PB2), influenza A acidic protein (PA), influenza B matrix (M), influenza B non-structural protein (NS), and the RSV A and RSV B nucleocapsid. A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert Xpress System. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the RT-PCR reaction. The SPC also ensures that the RT-PCR reaction conditions (temperature and time) are appropriate for the amplification reaction and that the RT-PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The Xpert Xpress CoV-2/Flu/RSV plus test is designed for use with NPS or NS specimens collected with nylon flocked swabs and placed into viral transport medium (VTM), Universal Transport Medium (UTM), or eNAT®. The ancillary specimen collection kits, swabs and transport media validated for use with the Xpert Xpress CoV-2/Flu/RSV plus test include:

• Nasopharyngeal Sample Collection Kit for Viruses
  • Copan UTM® 3C057N (Flexible Minitip Flocked Swab with UTM® Medium O without Beads)
  • Copan eNAT® Molecular Collection and Preservation Medium P/N 6U074S01 о (Flexible Minitip Flocked Swab with eNAT® Medium)
• Becton Dickinson Universal Viral Transport Kit P/N 220531 (Flexible Minitip o Flocked Swab with UVT Medium)
• Nasal Sample Collection Kit for Viruses
  • Copan UTM® 3C064N (Regular Flocked Swab with UTM® Medium without O Beads)
  • Copan eNAT® Molecular Collection and Preservation Medium P/N 6U073S01 O (Regular Flocked Swab with eNAT® Medium)
• Alternatively, swabs and transport media can be obtained separately: ●
  • Nylon flocked swab (Copan P/N 502CS01, 503CS01) o
  • Viral transport medium, 3 mL (Copan P/N 330C, 3C047N, BD Universal O Transport Medium, Remel M4RT or Remel M5)

These ancillary reagents allow NPS and NS specimens from patients to be collected, preserved and transported to laboratory prior to analysis with the Xpert Xpress CoV-2/Flu/RSV plus test.

The provided document is a 510(k) Summary for the Cepheid Xpert Xpress CoV-2/Flu/RSV plus test. It details the performance studies conducted to demonstrate substantial equivalence to a predicate device. Here's a breakdown of the acceptance criteria and study proving the device meets them, based on the provided text:

Acceptance Criteria and Reported Device Performance

The acceptance criteria are implicitly demonstrated through the reported performance in both analytical and clinical studies, aiming for high levels of agreement with established methods. The summarized performance data serves as the proof that the device meets these (implied) acceptance criteria.

Table of Acceptance Criteria and Reported Device Performance:

Since explicit acceptance criteria values (e.g., "PPA must be >= 95%") are not explicitly stated in the provided text as separate criteria, I will infer them from the reported strong performance and the nature of a 510(k) submission, where substantial equivalence to a predicate device is the goal. The reported performance is the validation that it meets the expected performance for such a device.

Ask a specific question about this device

The Xpert® MRSA/SA Skin and Soft Tissue Infection test (Xpert MRSA/SA SSTI test) performed on the GeneXpert® Instrument Systems is a qualitative in vitro diagnostic test intended for the detection of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from skin and soft tissue infection swabs. The test utilizes automated real-time polymerase chain reaction (PCR) to detect MRSA/SA DNA. The Xpert MRSA/SA SSTI test is indicated for use in conjunction with other laboratory tests, such as microbiology culture, and clinical data available to the clinician as an aid in the detection of MRSA/SA from skin and soft tissue infections. The Xpert MRSA/SA SSTI test is not intended to monitor treatment for MRSA/SA infections. Concomitant cultures for SA and MRSA are necessary to recover organisms for susceptibility testing or epidemiological typing. In a mixed culture containing MRSA/SA and other organisms (e.g., Gram-negative bacilli, yeast), results can be false negative or variable depending on the concentration of MRSA/SA present, particularly if the concentration of MRSA/SA is close to the limit of detection (LoD) of the test.

The Xpert MRSA/SA SSTI (Xpert MRSA/SA Skin and Soft Tissue Infection) test is an automated in vitro diagnostic DNA test for the qualitative, simultaneous detection of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) directly from skin and soft tissue specimen swabs. The specimen is collected on a double swab, one of which is placed in a tube containing elution reagent. Following brief vortexing, the eluted material is transferred to a different, uniquely labeled sample chamber of a disposable fluidic cartridge (the Xpert MRSA/SA SSTI cartridge).

The test is performed on the GeneXpert® Instrument Systems (comprised of the GeneXpert® Dx System, GeneXpert® System with Touchscreen, and GeneXpert® Infinity System). In the GeneXpert® Instrument Systems, sample preparation, amplification, and real-time detection are all fully automated and completely integrated. The platform requires the use of singleuse disposable cartridges that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized.

The user initiates a test from the system user interface of the GeneXpert® Instrument Systems platform and places the cartridge with sample into a GeneXpert® instrument system which performs hands-off real-time, multiplex polymerase chain reaction (PCR) for detection of SA and MRSA DNA.

Depending upon the specific instrument, a GeneXpert® instrument system may contain 1–80 modules, each which are randomly accessible and capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary ICORE® thermocycler for performing real-time PCR and detection.

The Xpert MRSA/SA SSTI test kit includes reagents for the simultaneous detection of the target organisms, SA and MRSA. The primers and probes in the Xpert MRSA/SA SSTI test detect nucleic acid sequences of the staphylococcal protein A (spa), the gene for methicillin/oxacillin resistance (mecA), and staphylococcal cassette chromosome (SCCmec) inserted in the SA chromosomal attB site.

The test includes a sample processing control (SPC) to control for adequate processing of the target bacteria and to monitor the presence of inhibitor(s) in the PCR assay. The SPC also ensures that the PCR conditions (temperature and time) are appropriate for the amplification reaction and that the PCR reagents are functional. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

The Xpert MRSA/SA SSTI test performed on the GeneXpert® Instrument Systems provides results in approximately 62 minutes.

The provided text is a 510(k) summary for a medical device called Xpert MRSA/SA SSTI. It describes a diagnostic test for Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from skin and soft tissue infection swabs, performed on the GeneXpert Instrument Systems.

The document does not contain information about the design of a study to prove acceptance criteria using a test set of data with expert ground truth, human reader performance, or multi-reader multi-case studies.

Instead, it details a Special 510(k) submission to modify an already cleared and legally marketed device (Xpert MRSA/SA SSTI, K080837). The specific modification is to include the GeneXpert® Infinity System instruments as a compatible platform for the test.

Therefore, the performance data presented is focused on demonstrating that the performance of the test on the new instrument platform (GeneXpert Infinity) is equivalent to its performance on previously cleared platforms (GeneXpert Dx System, GeneXpert System with Touchscreen). This is a bridging study rather than a primary clinical validation or an AI performance study as implied by many of the questions.

Given this, I cannot answer all your questions as the relevant information is not in the provided text. However, I will answer what is available and clarify what is missing.

Acceptance Criteria and Reported Device Performance

The acceptance criteria here refer to demonstrating equivalent performance of the Xpert MRSA/SA SSTI test when run on the new GeneXpert Infinity System compared to the previously cleared GeneXpert Dx System.

Study Details (Based on available information)

1. Sample size used for the test set and the data provenance:

   • The document mentions "contrived positive (MRSA cells added to negative matrix) and negative (negative matrix only) samples" for functional testing. It does not provide the specific number of samples (sample size) used in these studies.
   • Data Provenance: The data appears to be prospective as it's generated from specific verification studies ("prepared cartridge hold time study and functional testing") conducted for this 510(k) submission. The country of origin is not specified but implicitly North American given the FDA submission.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • This is a molecular diagnostic test, not an AI image analysis device. The "ground truth" for the functional testing would be the known concentration/presence of MRSA/SA cells in the contrived samples. This is established by the assay design and sample preparation, not by expert interpretation.
   • Therefore, this question does not apply to the type of study described.

3. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

   • Not applicable. This relates to expert consensus in interpreting complex data, which is not the ground truth methodology for this type of molecular test. The measurements (Ct values, presence/absence of signal) are quantitative and objective.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No, an MRMC study was not done. This is a diagnostic device for detecting specific DNA sequences, not an AI-powered device assisting human readers.

5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

   • The device itself (Xpert MRSA/SA SSTI test on the GeneXpert Instrument Systems) is a standalone automated diagnostic test. Its "performance" is the detection of specific DNA sequences. The studies assess the instrument's ability to run the test and yield equivalent results. The "functional testing" mentioned is effectively the standalone performance of the assay on the new instrument.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

   • The ground truth for the functional testing was contrived samples with known positive and negative status (e.g., negative matrix, or MRSA cells added to negative matrix where the concentration of MRSA/SA is known). This allows for direct assessment of sensitivity and specificity against a known standard.

7. The sample size for the training set:

   • This device is based on real-time PCR technology, not machine learning that requires a "training set" in the conventional sense. The test's probes and primers are designed based on biological knowledge of the target sequences.
   • Therefore, this question does not apply.

8. How the ground truth for the training set was established:

   • Not applicable, as there is no traditional "training set" for this type of diagnostic device.

Ask a specific question about this device

The Xpert® vanA test performed on the GeneXpert® Instrument Systems is a qualitative in vitro diagnostic test designed for detection of the vanA gene sequence associated with vancomycin resistance in bacteria obtained from rectal swab specimens from patients at risk for intestinal colonization with vancomycin-resistant bacteria. The test utilizes automated real-time polymerase chain reaction (PCR) to detect the vanA gene that is frequently associated with vancomycin-resistant enterococci (VRE). The Xpert vanA test is intended to aid in the recognition, prevention, and control of vancomycin-resistant organisms that colonize patients in healthcare settings. The Xpert vanA test is not intended to diagnose infections caused by vancomycin-resistant bacteria nor to guide or monitor treatment for vancomycin-resistant bacterial infections. Concomitant cultures are necessary to recover organisms for identification of vancomycin-resistant bacteria, antimicrobial susceptibility testing, and for epidemiological typing.

The Xpert van4 test is an automated in vitro diagnostic test for the qualitative detection of the vanA gene sequence associated with vancomycin resistance in bacteria obtained directly from rectal swab specimens. The specimen is collected on a double swab, one of which is placed in a tube containing sample reagent. Following brief vortexing, the content of the sample reagent is transferred to the uniquely labeled Sample Chamber of a disposable fluidic cartridge (the Xpert vanA cartridge). The user initiates a test from the user interface of the GeneXpert® instrument system platform and places the cartridge with sample into the GeneXpert® instrument system which performs hands-off real-time, multiplex polymerase chain reaction (PCR) for the detection of vanA DNA.

In the GeneXpert® Instrument Systems (comprised of the GeneXpert® Dx System, GeneXpert® System with Touchscreen, and GeneXpert® Infinity System), sample preparation, amplification, and real-time detection are all fully automated and completely integrated. The platform requires the use of single-use disposable cartridges that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized.

Depending on the specific instrument, a GeneXpert® instrument system may contain 1-80 modules, each of which are randomly accessible and capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE thermocycler for performing real-time PCR and detection.

The Xpert van4 test includes reagents for the detection of the gene for vancomycin resistance (van4) as well as an internal sample processing control (SPC) to control for adequate processing of the target bacteria and to monitor the presence of inhibitor(s) in the PCR assay. The SPC also ensures that the PCR conditions (temperature and time) are appropriate for the amplification reaction and that the PCR reagents are functional. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

The Xpert van 4 test performed on the GeneXpert® Instrument Systems provides results in less than 45 minutes.

Each instrument in the GeneXpert® instrument family is equipped with a Windows OS-based personal computer that is preloaded with software applications for running the tests and viewing the results, as described in Table 1.

The provided text describes a 510(k) premarket notification for the Cepheid Xpert vanA test. This submission is for a modification to an already cleared device (Xpert vanA, K092953) to include the GeneXpert Infinity System instruments. As such, the document primarily focuses on demonstrating that the performance of the modified device is equivalent to the predicate device and does not present a full de novo study with a comprehensive set of acceptance criteria and performance statistics like sensitivity and specificity against a clinical ground truth.

Here's an analysis of the available information:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal acceptance criteria with numerical targets for the verification studies. Instead, it describes "verification studies" aiming to show equivalence to the predicate device. The performance is reported qualitatively as "100% agreement of reportable results" and "no statistically significant differences in Ct values."

2. Sample Size Used for the Test Set and Data Provenance

The document mentions "both contrived positive (vancomycin-resistant (vanA) Enterococcus faecalis cells added to negative matrix) and negative matrix only) samples" for functional testing. However, it does not specify the sample size for these contrived samples.

The data provenance is from verification studies conducted by the manufacturer (Cepheid) to demonstrate the performance of the Xpert vanA test on the GeneXpert Infinity System instruments. The samples are contrived, meaning they were prepared in a laboratory setting, rather than derived from a patient population (i.e., not prospective or retrospective clinical data in the traditional sense).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

Given that the test set consisted of "contrived positive" and "negative matrix only" samples, the ground truth was established by the known composition of these laboratory-prepared samples. There is no mention of external experts or clinical adjudication for these ground truths, as the samples were artificially created with a defined vanA status.

4. Adjudication Method for the Test Set

No explicit adjudication method is mentioned. For contrived samples with a known composition, formal adjudication by a panel of experts is typically not performed or necessary. The "ground truth" is inherent in the preparation of the samples.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

This question is not applicable to this submission. The Xpert vanA test is a qualitative in vitro diagnostic test that uses automated real-time PCR to detect the vanA gene sequence. It is a fully automated system, and human interpretation of results is minimal (typically reading a "detected" or "not detected" output). There is no "AI" or "human reader" component in the diagnostic process that would warrant an MRMC study or an assessment of human reader improvement with AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, the performance evaluated here is essentially standalone (algorithm only). The Xpert vanA test is an automated system where sample preparation, amplification, and real-time detection are fully integrated. The "device performance" refers to the automated output of the system.

7. The Type of Ground Truth Used

The ground truth for the verification studies was based on known, contrived samples. For the "contrived positive" samples, the ground truth was the presence of vanA positive Enterococcus faecalis cells. For "negative matrix only" samples, the ground truth was the absence of vanA.

8. The Sample Size for the Training Set

This document does not provide information about a "training set." This submission focuses on verification studies for a modification to a previously cleared device. Diagnostic devices like this typically undergo extensive development and validation, but the details of the initial development (including training sets for algorithms, if any) are not part of this specific 510(k) summary for a modification. The test is based on PCR, not machine learning that would require a distinct "training set."

9. How the Ground Truth for the Training Set Was Established

Since no training set is mentioned or applicable in the context of this PCR-based diagnostic device and modification, how its ground truth was established is not provided in the document.

Ask a specific question about this device

The Xpert® SA Nasal Complete test performed on the GeneXpert® Instrument Systems is a qualitative in vitro diagnostic test designed for detection of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from nasal swabs in patients at risk for nasal colonization. The test utilizes automated real-time polymerase chain reaction (PCR) to detect MRSA/SA DNA. The Xpert SA Nasal Complete test is intended to aid in the prevention and control of MRSA/SA infections in healthcare settings. The Xpert SA Nasal Complete test is not intended to diagnose, guide or monitor treatment for MRSA/SA infections, or provide results of susceptibility to methicillin. A negative result does not preclude MRSA/SA nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.

The Xpert SA Nasal Complete test is an automated in vitro diagnostic DNA test for the qualitative, simultaneous detection of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) directly from nasal swabs. The specimen is collected on a double swab, one of which is placed in a tube containing elution reagent. Following brief vortexing, the eluted material is transferred to different, uniquely-labeled chamber of the disposable fluidic cartridge (the Xpert SA Nasal Complete cartridge). The user initiates a test from the user interface of the GeneXpert® Instrument Systems and places the cartridge with sample into the GeneXpert® Instrument System platform, which performs hands-off real-time, multiplex polymerase chain reaction (PCR) for detection of S. aureus (including MRSA) DNA.

In the GeneXpert® Instrument Systems (comprised of the GeneXpert® Dx Systems, GeneXpert® System with Touchscreen, and GeneXpert® Infinity Systems), sample preparation, amplification, and real-time detection are all fully-automated and completely integrated. The platform requires the use of single-use disposable cartridges that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized.

Depending on the specific instrument, the GeneXpert® Instrument Systems may contain 1–80 modules, each of which are randomly accessible and capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE thermocycler for performing real-time PCR and detection.

The Xpert SA Nasal Complete test kit includes reagents for the simultaneous detection of SA and MRSA targets. The primers and probes provided in the Xpert SA Nasal Complete test kit detects nucleic acid sequences of the staphylococcal protein A (spa), the gene for methicillin/oxacillin resistance (mecA), and staphylococcal cassette chromosome (SCCmec) inserted in the SA chromosomal attB site.

The Xpert SA Nasal Complete cartridge includes a sample processing control (SPC) to control for adequate processing of the target bacteria and to monitor the presence of inhibitor(s) in the PCR assay. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dve stability.

The Xpert SA Nasal Complete test performed on the GeneXpert® Instrument Systems provides results in approximately 65 minutes.

Each instrument in the GeneXpert® Instrument family is equipped with a Windows OS-based personal computer that is preloaded with software applications for running the tests and viewing the results, as described in Table 1.

Acceptance Criteria and Study Details for Xpert SA Nasal Complete (K243070)

This submission (K243070) seeks to modify the existing Xpert SA Nasal Complete device (K100822) to include the GeneXpert® Infinity Systems instruments in its compatible instrument family. The study described focuses on demonstrating equivalent performance on the new instrument systems.

1. Table of Acceptance Criteria and Reported Device Performance

The provided document doesn't explicitly state quantitative acceptance criteria for clinical performance (e.g., sensitivity, specificity) for this specific 510(k) submission (K243070). This is likely because the core assay and its clinical performance were extensively validated and accepted during the original clearance of K100822, and this submission focuses on adding new compatible instruments while demonstrating equivalent performance.

However, based on the studies conducted, the implicit acceptance criteria relate to demonstrating equivalent performance on the new GeneXpert Infinity Systems compared to the predicate device run on previously cleared GeneXpert systems.

2. Sample Size Used for the Test Set and Data Provenance

The document describes two types of studies impacting the acceptance criteria:

• Prepared Cartridge Hold Time Study:

  • Sample Size: Not explicitly stated. The study involved verifying a maximum acceptable hold time. This would typically involve testing multiple samples at various time points within and beyond the proposed hold time.
  • Data Provenance: Not specified, but likely laboratory-based controlled studies.

• Functional Testing:

  • Sample Size: Not explicitly stated. The study used "both contrived positive (MRSA added to negative matrix) and negative (negative matrix only) samples." It also notes "Each target of the Xpert SA Nasal Complete test was analyzed." This implies a sufficient number of samples to represent positive and negative outcomes for both SA and MRSA targets.
  • Data Provenance: Not specified, but based on the description of "contrived positive" and "negative matrix," it is a retrospective laboratory-based study using controlled samples. The materials used (e.g., negative matrix) would be laboratory-sourced.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

Not Applicable for this particular submission. The ground truth for the functional testing was established by the nature of the contrived samples:

• Contrived positive samples: MRSA added to negative matrix, meaning the positive status was known and intentionally created.
• Negative samples: Negative matrix only, meaning the negative status was known and intentionally created.

This type of study does not require human expert interpretation to establish the ground truth of the samples.

4. Adjudication Method for the Test Set

Not Applicable. As the ground truth was established by the deliberate creation of contrived positive and negative samples, no adjudication by human experts was required to determine the true status of the samples.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done

No, a MRMC comparative effectiveness study was not done. This submission (K243070) is for a device modification to expand compatible instruments rather than to assess human reader improvement with AI assistance. The device in question is an automated in vitro diagnostic test that provides a qualitative result (positive/negative) directly, without requiring human interpretation for its primary output.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) Was Done

Yes, a standalone performance study was effectively done. The Xpert SA Nasal Complete test is an automated nucleic acid amplification test (NAAT). The "functional testing" described assesses the device's ability to correctly identify contrived positive and negative samples when run on the new GeneXpert Infinity Systems instruments, independently determining the presence or absence of the target DNA. This is a standalone performance evaluation of the device itself.

7. The Type of Ground Truth Used

The ground truth used for the functional testing was established by the deliberate creation of contrived samples. This includes:

• Contrived positive samples: MRSA added to a negative matrix, where the presence of the pathogen (MRSA) is known and controlled.
• Negative samples: Negative matrix only, where the absence of the pathogen is known and controlled.

This methods ensures a definitive and known ground truth.

8. The Sample Size for the Training Set

Not applicable/Not explicitly stated. The Xpert SA Nasal Complete test is a PCR-based diagnostic with specific primers and probes for target DNA. It is not typically a machine learning/AI model that undergoes "training" in the traditional sense with a distinct training set. The assay's design (primers, probes, thermocycling protocols) would have been developed and optimized during its initial development, but this isn't referred to as a "training set" in the context of this type of device. The current submission is a modification focusing on instrument compatibility.

9. How the Ground Truth for the Training Set Was Established

Not applicable. As noted above, the concept of a "training set" and its associated ground truth establishment is not directly relevant to this PCR-based diagnostic device in the context of this submission. The assay's analytical performance and target specificity are inherent to its biochemical design.

Ask a specific question about this device

The Xpert HCV test, performed on the GeneXpert Xpress System, is an automated in vitro reverse transcription polymerase chain reaction (RT-PCR) test for the qualitative detection of hepatitis C virus (HCV) RNA in human fingerstick K2-EDTA whole blood from adult individuals at risk and/or with signs and symptoms of HCV infection with or without antibody evidence of HCV infection. Detection of HCV RNA indicates that the virus is replicating and therefore is evidence of active infection. Detection of HCV RNA does not discriminate between acute and chronic states of infection.

The Xpert HCV test is not intended for monitoring patients undergoing treatment or for use in screening blood, plasma, or tissue donors.

The Xpert HCV test, is an automated qualitative in vitro reverse transcription polymerase chain reaction (RT-PCR) test. The Xpert HCV test is performed on the GeneXpert Xpress System. With this system an operator can run the test by performing four steps: 1) mix the specimen. 2) transfer the liquid sample to the cartridge with a transfer pipette, 3) run the test on the instrument, and 4) read the results.

The GeneXpert Xpress System (Hub configuration) consists of a GeneXpert IV instrument that conducts the sample preparation, nucleic acid amplification and real-time fluorescent signal detection for the test, and a GeneXpert Hub with preloaded GeneXpert Xpress software for running the tests and viewing the results. The GeneXpert Hub accessory integrates the computer, touchscreen monitor and barcode scanner. Each of the GeneXpert modules in the GeneXpert IV instrument can perform separate sample preparation and testing. The module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE (Intelligent Cooling/Heating Optical Reaction) thermocycler for performing real-time PCR and RT-PCR and detection.

The Xpert HCV test requires the use of a single-use disposable GeneXpert cartridge that contains all necessary reagents for the detection of HCV RNA. Because the cartridges are self-contained, the risk of cross-contamination between samples is minimized. The Xpert HCV test includes reagents for the detection of HCV RNA in clinical specimens as well as a sample processing control (SPC) and internal control high (IC-H) used to control for adequate processing of the target and to monitor the presence of inhibitor(s) in the RT and PCR reactions. The Probe Check Control (PCC) verifies reagent rehydration. PCR tube filling in the cartridge, probe integrity, and dye stability. The Sample Volume Adequacy (SVA) control ensures the sample was correctly added to the cartridge and verifies that the correct volume of sample has been added to the sample chamber.

The Xpert HCV test is designed for use with human K2-fingerstick EDTA whole blood. The BD Microtainer for capillary whole blood collection was validated for use with the Xpert HCV test. After collecting human fingerstick EDTA whole blood in the BD Microtainer, a 100μl aliquot of the specimen is transferred to the sample chamber of the Xpert HCV cartridge using the transfer pipette supplied in the Xpert HCV kit.

The sample results are interpreted by the GeneXpert Xpress System from measured fluorescent signals and embedded calculation algorithms and are shown in the View Results window. It also reports if the test has encountered an instrument error or produces no result and needs to be repeated.

This document describes the evaluation of the Xpert HCV test for an automatic Class III designation. The test is an automated qualitative reverse transcription polymerase chain reaction (RT-PCR) test for the qualitative detection of hepatitis C virus (HCV) RNA.

Here's a breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for the Xpert HCV test are implied by the reported performance in both analytical and clinical studies. For analytical performance, the agreement rates for precision and reproducibility are presented. For clinical performance, Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) compared to a Patient Infected Status (PIS) algorithm are key metrics.

2. Sample Sizes Used for the Test Set and Data Provenance

• Precision Study Test Set: The precision study used a total of 60 replicates per panel member (e.g., negative, GT1a 1.5x LoD, etc.). The study was conducted in a blinded and randomized manner.
• Multi-Site Reproducibility Study Test Set: A total of 90 replicates per panel member were tested across three sites. The study was blinded and randomized.
• Clinical Study Test Set: 1,012 fingerstick whole blood (FS) specimens were initially collected. After exclusions due to protocol deviations, unresolved non-determinate results, and non-evaluable comparator test results, 982 FS samples were included in the performance calculations (Table 13, 14).
• Non-Viral Hepatitis Samples Study: 78 FS samples from individuals with non-viral hepatitis were included, with 68 being evaluable for performance comparison (Table 15).
• Data Provenance for Clinical Study: Prospective, all-comers blinded clinical study conducted at 15 CLIA waived sites located in the US.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not specify the number or qualifications of experts used to establish the ground truth for the test set. Instead, it states that the "patient infected status (PIS) algorithm based on results from an FDA approved HCV RNA test and an antibody test" served as the comparator/ground truth for the clinical study. This implies that the ground truth was established by the performance of these approved reference tests, rather than by a panel of human experts directly reviewing the samples.

4. Adjudication Method for the Test Set

The document does not describe an explicit adjudication method (e.g., 2+1, 3+1) involving human experts for the test set. The clinical study's ground truth was established by comparing the Xpert HCV test results to the "patient infected status (PIS) algorithm based on results from an FDA approved HCV RNA test and an antibody test." Any discrepancies would likely be resolved by the established reference method rather than expert adjudication of the fingerstick samples themselves. The retesting of "Two (2) specimens (1 false positive and 1 false negative) with suspicion of specimen handling and testing errors" suggests a method for investigating discrepancies, but not a general expert adjudication for all cases.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

A Multi-Reader Multi-Case (MRMC) comparative effectiveness study comparing human readers with and without AI assistance was not done. This device is an automated qualitative RT-PCR test, and its output (HCV DETECTED/NOT DETECTED) is a direct result from the instrument, not interpreted by human readers in the traditional sense that an AI would assist. The "operators" mentioned in the analytical studies are those performing the physical test steps, not interpreting diagnostic images or complex medical data.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, a standalone performance evaluation was done. The Xpert HCV test is an automated system where the "sample results are interpreted by the GeneXpert Xpress System from measured fluorescent signals and embedded calculation algorithms" and results are "displayed in the View Results window." The clinical study (Section VI.C.3) directly evaluates the performance of this automated system against the patient infected status algorithm. The operators in the study are described as "untrained," further emphasizing the standalone nature of the device's interpretation.

7. The Type of Ground Truth Used

The ground truth used for the clinical study was the Patient Infected Status (PIS) algorithm, which was "based on results from an FDA approved HCV RNA test and an FDA approved HCV antibody test." This constitutes a form of established clinical diagnosis reference standard (or "outcomes data" in a broader sense of established clinical status).

8. The Sample Size for the Training Set

The document does not specify a sample size for a training set. As an RT-PCR diagnostic device, the "training" of the device involves the internal development and calibration of the assay (e.g., primer and probe design, thermal cycling conditions, fluorescent signal thresholds, embedded calculation algorithms) by the manufacturer based on analytical studies and known HCV characteristics, rather than a classical machine learning training phase on a large clinical dataset.

9. How the Ground Truth for the Training Set Was Established

Since no explicit training set is mentioned in the context of machine learning, there is no description of how ground truth for a training set was established. The development of the assay likely involved extensive analytical studies (e.g., determining LoD for various genotypes, specificity, interference) using well-characterized HCV strains and clinical samples to establish the assay's performance parameters and the embedded algorithms' decision rules. These characterization efforts would form the basis of the device's "knowledge," but it's not a "training set" in the sense of supervised learning for an AI algorithm that learns from labeled data.

Ask a specific question about this device